Literature DB >> 2758726

Time to stop counting the tablets?

T Pullar1, S Kumar, H Tindall, M Feely.   

Abstract

We attempted to assess compliance using both a pharmacologic indicator (low-dose phenobarbital) and a return tablet count in 225 patients who were taking part in three separate studies. There were 216 patients (96%) who kept a follow-up appointment after 28 days; 161 patients appeared to have good compliance (90% to 109%) by return tablet count. Of these 161 patients, 51 (32%) had plasma phenobarbital concentrations (corrected for dose and weight) that were less than 90% of the lowest value previously found in normal volunteers, which suggested poorer compliance. When compared with the age-related volunteer values, 77 (48%) had values that were less than 90% of the lowest volunteer value. There were 6 of 10 patients with apparently excessive (greater than or equal to 110%) compliance by return tablet count and 4 of 12 who failed to return their container who also had phenobarbital concentrations that were less than 90% of the lowest volunteer value. We concluded that return tablet count grossly overestimates compliance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2758726     DOI: 10.1038/clpt.1989.121

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  55 in total

Review 1.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  What is the cardioprotective role of hormone replacement therapy?

Authors:  Howard N Hodis; Wendy J Mack; Roger Lobo
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

3.  A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteers.

Authors:  E Hardy; S Kumar; S Peaker; M Feely; T Pullar
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

4.  Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Authors:  Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng
Journal:  Rapid Commun Mass Spectrom       Date:  2018-03-15       Impact factor: 2.419

5.  Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback.

Authors:  Joy M Schmitz; Shelly L Sayre; Angela L Stotts; Jennifer Rothfleisch; Marc E Mooney
Journal:  J Behav Med       Date:  2005-04

Review 6.  Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Authors:  Thomas Kerr; John Walsh; Elisa Lloyd-Smith; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

Review 7.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

8.  Measures and predictors of varenicline adherence in the treatment of nicotine dependence.

Authors:  Annie R Peng; Mark Morales; E Paul Wileyto; Larry W Hawk; Paul Cinciripini; Tony P George; Neal L Benowitz; Nicole L Nollen; Caryn Lerman; Rachel F Tyndale; Robert Schnoll
Journal:  Addict Behav       Date:  2017-07-12       Impact factor: 3.913

9.  Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures.

Authors:  V Rabenda; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-01-16       Impact factor: 4.507

10.  Compliance with medication in the Helsinki Heart Study.

Authors:  H Mäenpää; V Manninen; O P Heinonen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.